glabellar lines pipeline insight

DelveInsight’s, “Glabellar Lines - Pipeline Insight, 2025,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Glabellar Lines pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• Global coverage

Glabellar Lines Understanding

Glabellar Lines: Overview

Glabellar lines or glabella lines appear in the glabella, the skin over your forehead, between and above the eyebrows and right above the nose. When you wrinkle your face by talking, yawning, laughing, or making expressions, the glabella is the skin most affected by the muscle activity beneath the surface. Over time, as a result of a combination of causes including genetics, skin tightness, muscle activity, face shape, and various intrinsic and extrinsic causes, the lines that appear in your glabella may remain permanently, evolving into wavy furrows in the forehead. These are known as glabellar lines and they can continuously worsen over time if not treated. Glabella lines and frown lines are often used interchangeably to describe the lines above the nose and around the forehead, with some even using the term “glabella frown lines.” Glabella lines and other wrinkles can be worsened by too much physical stretching of the face, but that is just one of the factors that can cause and worsen these lines. Although the most straightforward and effective way of reducing glabellar lines is through Botox and other injectables, you can also attempt to minimize your frown lines with natural methods. Altering your diet and implementing a potent skincare regimen may not be enough to wipe away these lines completely, but they can make your skin healthier and less susceptible to facial lines. Keeping the skin hydrated is one of the easiest ways to prevent lines from forming. While the body produces natural oils that can keep the skin hydrated, exposure to harsh environmental factors and using certain cosmetic and even skincare products can strip essential oils from the face. Aim to moisturize your skin at least twice a day, especially the glabellar area.

 

"Glabellar Lines- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glabellar Lines pipeline landscape is provided which includes the disease overview and Glabellar Lines treatment guidelines. The assessment part of the report embraces, in depth Glabellar Lines commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glabellar Lines collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Glabellar Lines R&D. The therapies under development are focused on novel approaches to treat/improve Glabellar Lines. 

Glabellar Line Recent Developments

• In April 2025, AbbVie submitted a Biologics License Application (BLA) to the FDA for trenibotulinumtoxinE (TrenibotE) as a treatment for moderate to severe glabellar lines. The submission highlights TrenibotE's potential to offer faster onset and shorter treatment duration, aiming to transform the aesthetic toxin treatment landscape.

Glabellar Lines Emerging Drugs Chapters

This segment of the Glabellar Lines report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Glabellar Lines Emerging Drugs

 

Daxibotulinumtoxin A - Revance Therapeutics

Daxibotulinumtoxin A for Injection, is an investigational neuromodulator product. DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA and is currently under regulatory review. It is aiming to establish a new, premium, long-lasting neuromodulator category. DaxibotulinumtoxinA combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. The FDA accepted for review the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection in the treatment of moderate to severe glabellar (frown) lines.

 

ATGC-100: EuBiologics

ATGC-100 is botulinum toxin A just like Allergan’s Botox. Eubiologics and ATGC are jointly developing ATGC-100. Botulinum Toxin is a toxin produced only by the gram-positive anaerobic bacteria, Clostridium botulinum, inducing temporary muscle paralysis by reversibly blocking the secretion of acetylcholine at a neuromuscular junction

 

BoNTE : AbbVie

BoNTE is a toxin being investigated for treatment of glabellar lines. The drug is currently being investigated in phase 2 stage of development, for the treatment of glabellar lines.

 

IPN-10200: Ipsen

IPN-10200 , is a Longer-acting neurotoxin. IPN-10200 is currently being investigated in Phase I/II. The purpose of this study is to assess the safety and efficacy profile of increasing doses of IPN10200 in comparison to placebo, with the aim to discover the doses(s) that offer the best efficacy/safety profile when used for the treatment of moderate to severe Upper Facial Lines.

AI-09: Eirion Therapeutics

Eirion is developing a next generation ready-to-use liquid injectable neuromodulator product called AI-09 for the treatment of glabellar (frown) lines. Eventually, AI-09 may be developed for other aesthetic and medical indications. AI-09 will be provided as a ready-to-use, liquid formulation, which contrasts favorably to currently commercialized neuromodulator products that all require reconstitution with saline in the physician's office before use. As well, in contrast to current injectable products, AI-09 does not contain human albumin, which carries a risk of disease transmission. AI-09 have been shown to be stable at room temperature for at least 3 months, which is also an advantage over current products that require shipping to and storage at the physician's office in frozen conditions. Eirion plans to file an IND for AI-09 later this year.

Further product details are provided in the report……..

Glabellar Lines: Therapeutic Assessment

This segment of the report provides insights about the different Glabellar Lines drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Glabellar Lines

There are approx. 4+ key companies which are developing the therapies for Glabellar Lines. The companies which have their Glabellar Lines drug candidates in the most advanced stage, i.e. Pre-Registration include, Revance Therapeutics.

 

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Glabellar Lines pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glabellar Lines: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glabellar Lines therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glabellar Lines drugs.

Glabellar Lines Report Insights

• Glabellar Lines Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Glabellar Lines Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Glabellar Lines drugs?
• How many Glabellar Lines drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glabellar Lines?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glabellar Lines therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glabellar Lines and their status?
• What are the key designations that have been granted to the emerging drugs?